After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
Ionis Pharmaceuticals Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Ionis Pharmaceuticals Inc is $12.07B. A total of 2.06 million shares were traded on the day, compared to an average of 2.75M shares.
In the most recent transaction, Birchler Brian sold 8,000 shares of IONS for 76.17 per share on Nov 06 ’25. After the transaction, the EVP, Corp and Development Ops now owns 48,826 company shares. In a previous transaction on Nov 06 ’25, Geary Richard S sold 33,038 shares at 75.72 per share. IONS shares that EVP, Chief Development Officer owns now total 59,657.
Among the insiders who sold shares, Geary Richard S disposed of 1,601 shares on Nov 05 ’25 at a per-share price of $75.01. This resulted in the EVP, Chief Development Officer holding 59,657 shares of IONS after the transaction. In another insider transaction, WENDER JOSEPH H sold 16,800 shares at $73.26 per share on Oct 30 ’25. Company shares held by the Director now total 75,235.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, IONS has a high of $76.78 and a low of $23.95.
As of this writing, IONS has an earnings estimate of -$1.23 per share for the current quarter. EPS was calculated based on a consensus of 8.0 estimates, with a high estimate of -$0.81 per share and a lower estimate of -$1.47. The company reported an EPS of -$0.43 in the last quarter
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. IONS’s latest balance sheet shows that the firm has $2.11B in Cash & Short Term Investments as of fiscal 2021. There were $1.25B in debt and $240.55M in liabilities at the time. Its Book Value Per Share was $3.84, while its Total Shareholder’s Equity was $771.74M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IONS is Buy with a score of 4.42.
